Most Read Articles
one year ago
Age at onset significantly influences long-term clinical outcomes and health-related quality of life in paediatric ischaemic stroke survivors based on a study.
Elvira Manzano, one year ago
Valsartan/sacubitril (formerly LCZ696), recently approved by the US Food and Drug Administration for treating heart failure, may also be beneficial for reducing blood pressure (brachial and central aortic pressure) as well as arterial stiffness compared with angiotensin receptor blocker olmesartan.
one year ago
New drug applications approved by US FDA as of 16 - 31 Dec 2015 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Catherine J Calderwood, MA (Cantab), MRCOG; Omar I Thanoon, MRCOG, 3 years ago

One of the many early physiological adaptations of pregnancy involves changes in the coagulation system, which promote coagulation and impair fibrinolysis. The physiological goal is to prepare for the haemostatic challenge of delivery. A ‘side effect’ of this change is an increased risk of thrombosis. All pregnant women are therefore at risk of thrombosis, compared with non-pregnant women. This risk is manifest from early in the first trimester until 4−6 weeks post partum.

Statins confer all-cause, pulmonary-related mortality benefits

9 days ago

Use of statins may reduce all-cause and pulmonary-related mortality in patients with chronic obstructive pulmonary disease (COPD), a study has shown.

The population-based cohort study included 39,678 COPD patients from the province of British Columbia in Canada. Statin exposure was established in the 12-month period after diagnosis. All-cause and pulmonary-related mortality, the respective primary and secondary outcomes, were evaluated in the 1-year period after exposure ascertainment.

Of the patients, 19.6 percent (n=7,775) had received at least one statin dispensed during the exposure ascertainment window. In the 1-year period after the window, a total of 1,446 all-cause deaths were recorded within the cohort.

Multivariate analysis found statin exposure to be associated with a 21-percent reduction in the risk of all-cause mortality (hazard ratio [HR], 0.79; 95 percent CI, 0.67 to 0.92; p=0.0016). The result was similar for pulmonary-related mortality, with statin exposure showing a protective effect (HR, 0.55; 0.32 to 0.93; p=0.02454). These associations persisted across different measures of statin exposure.

The present data suggest that there may be a specific subtype of COPD patients that could benefit from statin use, researchers said, explaining that statin’s impact on mortality may be attributed to the drug’s pleiotropic effects and known disease-modifying effects on cardiovascular comorbidities. [Chest 2009;136:376–380; COPD 2015;12:560–567]

Affecting around 380 million people globally, COPD is characterized by progressive airflow limitation and inflammation. Comorbidities associated with the disease are an important aspect of the respiratory disease. Specifically, cardiovascular disease has been shown to be more than two times more prevalent in patients with COPD than in the general population. Moreover, the risk of CVD-related mortality may increase as the severity of the COPD worsens.  This indicates that all-cause mortality has largely become the most relevant metric for outcomes in COPD patients. [Respirology 2016;21:697–704; Lancet Respir Med 2015;3:631–639; Eur Respir J 2006;28:1245–1257; Ann Epidemiol 2006;16:63–70; CHEST J 2005;128:2068–2075]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacy - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
one year ago
Age at onset significantly influences long-term clinical outcomes and health-related quality of life in paediatric ischaemic stroke survivors based on a study.
Elvira Manzano, one year ago
Valsartan/sacubitril (formerly LCZ696), recently approved by the US Food and Drug Administration for treating heart failure, may also be beneficial for reducing blood pressure (brachial and central aortic pressure) as well as arterial stiffness compared with angiotensin receptor blocker olmesartan.
one year ago
New drug applications approved by US FDA as of 16 - 31 Dec 2015 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Catherine J Calderwood, MA (Cantab), MRCOG; Omar I Thanoon, MRCOG, 3 years ago

One of the many early physiological adaptations of pregnancy involves changes in the coagulation system, which promote coagulation and impair fibrinolysis. The physiological goal is to prepare for the haemostatic challenge of delivery. A ‘side effect’ of this change is an increased risk of thrombosis. All pregnant women are therefore at risk of thrombosis, compared with non-pregnant women. This risk is manifest from early in the first trimester until 4−6 weeks post partum.